Yellow Fever Vaccine—Reply to S. Arya
1999
Reply to Concerns About Yellow Fever Vaccine Stability
publication
Author Information
Author(s): Monath T.P., Giesberg J.A., Fierros E.G.
Primary Institution: OraVax, Cambridge, Massachusetts, USA
Conclusion
The current cold-chain infrastructure in the U.S. ensures yellow fever vaccine stability, making additional validation unnecessary under current policies.
Supporting Evidence
- Yellow fever vaccines in the U.S. are stabilized and require proper storage like other vaccines.
- Empirical testing for vaccine effectiveness is difficult and expensive, and often unnecessary.
- The cold-chain infrastructure in the U.S. supports the stability of yellow fever vaccines.
Takeaway
The yellow fever vaccine is stored properly in the U.S., so there's no need to worry about it going bad like some other vaccines might.
Limitations
The findings may not apply to countries with less stable vaccine supply systems.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website